Welcome to our dedicated page for Roger news (Ticker: ROG), a resource for investors and traders seeking the latest updates and insights on Roger stock.
Rogers Corporation reports developments tied to its engineered materials business, including advanced electronic materials and elastomeric materials sold for EV/HEV, automotive safety and radar systems, mobile devices, renewable energy, wireless infrastructure, energy-efficient motor drives, industrial equipment and related applications. The company manufactures in the United States, Asia and Europe and serves original equipment manufacturers and component suppliers.
Recurring Rogers news includes quarterly and annual financial results, end-market demand across industrial, electronics and communications, and automotive markets, profitability and cost-improvement initiatives, product-development commentary, capital-structure disclosures, and board or executive governance updates.
On February 9, 2021, a fire occurred at Rogers Corporation's (NYSE:ROG) UTIS manufacturing facility in Ansan, South Korea. The site was evacuated without injuries, but the facility suffered extensive damage. The fire's cause is under investigation. This site produces eSorba® polyurethane foams, crucial for portable electronics, and will see operational disruptions, though the duration is yet unknown. The UTIS business accounts for less than 4% of Rogers' annual sales and employs about 50 people.
Rogers Corporation (NYSE:ROG) is set to announce its fourth quarter and full year 2020 results on February 18, following market close. This will be accompanied by a conference call at 5:00 pm ET, featuring key executives including President and CEO Bruce Hoechner. Investors can access the live webcast and presentation on Rogers' investor website. The company, with over 180 years of materials science experience, specializes in engineered materials for advanced connectivity, mobility applications, and more, operating globally across multiple countries.
Genentech announced positive topline results from two Phase III studies, TENAYA and LUCERNE, for its bispecific antibody faricimab in treating neovascular age-related macular degeneration (nAMD). Both studies met their primary endpoint, demonstrating that faricimab injections at intervals up to 16 weeks achieved comparable visual acuity to aflibercept given every 8 weeks. Approximately 45% of participants receiving faricimab were treated every 16 weeks, marking a significant milestone in treatment durability. Faricimab was generally well tolerated with no new safety concerns.
Genentech, part of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the FDA has accepted its supplemental New Drug Application (sNDA) for Esbriet® (pirfenidone) to treat unclassifiable interstitial lung disease (UILD) and granted Priority Review. A decision is expected by May 2021. This sNDA is based on a Phase II trial, the first randomized controlled study for UILD, indicating Esbriet may benefit patients. The treatment has previously received Orphan Drug and Breakthrough Therapy Designations from the FDA.
Genentech has received Breakthrough Therapy Designation (BTD) from the FDA for tiragolumab, an innovative cancer immunotherapy targeting TIGIT, in combination with Tecentriq for treating metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression. This marks the first anti-TIGIT molecule to receive BTD, based on promising results from the Phase II CITYSCAPE trial, which demonstrated improved overall response rates and progression-free survival. Genentech plans to further develop tiragolumab across multiple cancer types, aiming for significant advancements in treatment.
Genentech has received FDA approval for a shorter two-hour infusion time for Ocrevus (ocrelizumab) for patients with relapsing or primary progressive multiple sclerosis (MS) without prior serious infusion reactions. This decision follows data from the ENSEMBLE PLUS study, showing comparable infusion reaction rates between the two-hour and previous 3.5-hour infusions. Ocrevus is already the most prescribed MS medication in the U.S., with dosing every six months and approved in 94 countries.
Rogers Corporation (NYSE:ROG) has announced the appointment of Megan Faust and Keith Larson to its Board of Directors. Megan brings extensive experience in corporate finance as the CFO of Amkor Technology, while Keith has a strong background in corporate development from his tenure at Intel Corporation. The Board believes their expertise aligns well with Rogers' strategic growth priorities. This leadership change aims to enhance the company's operational model and drive future success in engineered materials.
Rogers Corporation (NYSE:ROG) will announce its third quarter 2020 results on October 29 after market close. A conference call will follow at 5:00 pm ET with President and CEO Bruce Hoechner, CFO Mike Ludwig, and CTO Bob Daigle. Investors can access a live webcast and slide presentation on their website. Rogers Corporation is a global leader in engineered materials, focusing on advanced connectivity and mobility applications, with a history exceeding 180 years in materials science.
Rogers Corporation has launched Griswold GripON, a next-generation natural sponge solution aimed at reducing slippage and skidding in various industries, including electronics and furniture. This new product features a high coefficient of friction, minimizes vibration, and reduces noise, while also preventing surface scratches. With customizable sizes and shapes, Griswold GripON is designed to meet diverse application needs, including skid-resistant solutions for electronic devices. The product reflects Rogers' commitment to innovation within its Elastomeric Material Solutions division.